Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

被引：0
|
作者：
Mauro, Michael [1 ]
Hochhaus, Andreas [2 ]
Hughes, Timothy [3 ,4 ]
Rea, Delphine [5 ]
Boquimpani, Carla [6 ]
Minami, Yosuke [7 ]
Apperley, Jane [8 ]
Garcia-Gutierrez, Valentin [9 ]
Kapoor, Shruti [10 ]
Espurz, Noemi [11 ]
Dhamal, Vishal [12 ]
Cortes, Jorge [13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Klinikum Jena, Jena, Germany
[3] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[4] Univ Adelaide, Adelaide, SA, Australia
[5] Hop St Louis, Paris, France
[6] State Inst Hematol Arthur Siquiera Cavalcanti, HEMORIO, Rio De Janeiro, Brazil
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[8] Ctr Haematol Imperial Coll London, London, England
[9] Hosp Univ Ramon & Cajal IRYCIS, Serv Hematol, Madrid, Spain
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Healthcare Private Ltd, Hyderabad, India
[13] Georgia Canc Ctr, Augusta, GA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CML; asciminib; TKI; ASCEMBL; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-398
引用
收藏
页码：S340 / S340
页数：1
相关论文
共 50 条
  • [1] Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Mauro, Michael
    Cortes, Jorge E.
    Apperley, Jane F.
    Gutierrez, Valentin Garcia
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sarah
    Zhang, Yifan
    Hochhaus, Andreas
    BLOOD, 2022, 140 : 6757 - 6759
  • [2] Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
    Rea, Delphine
    Hochhaus, Andreas
    Mauro, Michael J.
    Minami, Yosuke
    Lomaia, Elza
    Voloshin, Sergey
    Turkina, Anna
    Kim, Wook
    Apperley, Jane F.
    Cortes, Jorge E.
    Abdo, Andre
    Fogliatto, Laura Marie
    Kim, Dennis Dong Hwan
    le Coutre, Philipp
    Saussele, Susanne
    Annunziata, Mario
    Hughes, Timothy P.
    Chaudhri, Naeem
    Chee, Lynette
    Garcia-Gutierrez, Valentin
    Sasaki, Koji
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sara
    Bedoucha, Veronique
    Boquimpani, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S295 - S296
  • [3] Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.
    Rea, Delphine
    Mauro, Michael J.
    Hochhaus, Andreas
    Boquimpani, Carla
    Lomaia, Elza
    Voloshin, Sergey
    Turkina, Anna G.
    Kim, Dong-Wook
    Apperley, Jane
    Cortes, Jorge E.
    Sasaki, Koji
    Kapoor, Shruti
    Allepuz, Alex
    Quenet, Sara
    Bedoucha, Veronique
    Minami, Yosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
    Dahlen, Torsten
    Kockerols, Camille C. B.
    Ferreira, Germano
    Westerweel, Peter E.
    Mayer, Jiri
    Allepuz, Alex
    Wormser, David
    Yau, Lillian
    Zackova, Daniela
    BLOOD, 2022, 140 : 3889 - 3890
  • [5] A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).
    Mauro, Michael J.
    Hochhaus, Andreas
    Boquimpani, Carla
    Minami, Yosuke
    Allepuz, Alex
    Polydoros, Fotis
    Bedoucha, Veronique
    Aimone, Paola
    Rea, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors ( TKIs) in the Ascembl Trial
    Branford, Susan
    Hochhaus, Andreas
    Mauro, Michael
    Minami, Yosuke
    Rea, Delphine
    Boquimpani De Moura Freitas, Carla Maria
    Serrano-Fernandez, Pablo
    Obourn, Vanessa
    Bruederle, Andreas
    Espurz, Noemi
    Hughes, Timothy P.
    BLOOD, 2023, 142
  • [7] Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
    Hughes, Timothy
    Mauro, Michael
    Kim, Dong-Wook
    Cortes, Jorge
    Rea, Delphine
    Minami, Hironobu
    Breccia, Massimo
    DeAngelo, Daniel
    Hochhaus, Andreas
    Goh, Yeow-Tee
    le Coutre, Philipp
    Lang, Fabian
    Cacciatore, Silvia
    Aimone, Paola
    Stenson, Laura
    Polydoros, Fotis
    Talpaz, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S235 - S235
  • [8] Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Issa, Ghayas C.
    Larson, Richard A.
    Hughes, Timothy P.
    Hochhaus, Andreas
    Takahashi, Naoto
    Bombaci, Felice
    Wang, Jianxiang
    Kim, Dong-Wook
    Dong, Dennis
    Kim, Hwan
    Gu, Ennan
    Zhang, Yifan
    Kapoor, Shruti
    Agrawal, Nithya
    Jinwal, Rajendra
    Damon, Andrea
    Sadek, Islam
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S368 - S368
  • [9] Oral Asciminib (ABL001) vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Received ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): A Multicenter, Open-Label, Randomized, Phase 3 Study
    Mauro, Michael
    Boquimpani, Carla
    Minami, Yosuke
    Rea, Delphine
    Kemp, Charisse
    Schmitz, Shu-Fang Hsu
    Gopalakrishna, Prashanth
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S315 - S316
  • [10] Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
    Smith, B. Douglas
    Cortes, Jorge E.
    Rea, Delphine
    Mauro, Michael J.
    Patwardhan, Pallavi
    Maegawa, Rodrigo
    Zacker, Christopher
    Corbin, Regina
    Keeping, Sam
    Sasaki, Koji
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S334 - S334
12345